Top

19-11-2023 | Hepatic Encephalopathy | Review

Association between sarcopenia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review and meta-analysis

Authors: Yuanyuan Li, Yuxin Guo, Xiaoze Wang, Langli Gao

Abstract

Purpose

The association between the presence of sarcopenia in patients with cirrhosis and the onset of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) is yet to be established. We conducted a systematic review and meta-analysis to provide a thorough summary of the available evidence on this association.

Methods

A thorough search of the literature was performed in the PubMed, EMBASE, and Web of Science databases. The protocol was duly registered on PROSPERO (CRD42023398856). The hazard ratio (HR) and corresponding 95% confidence intervals (CIs) for the occurrence of HE after TIPS were extracted from studies comparing cirrhotic patients with and without sarcopenia. These data were then combined using a random-effect model.

Results

A total of 1135 patients from seven cohort studies that met our eligibility criteria were included in the meta-analysis. Our findings indicate a significantly higher risk of post-TIPS HE among cirrhotic patients with sarcopenia compared to those without sarcopenia (HR, 2.35; 95% CIs 1.32–4.19; p = 0.004; I² = 75%). The findings remained consistent across subgroups stratified by liver disease etiology, study location, and severity of hepatic dysfunction.

Conclusion

The study demonstrated that sarcopenia was strongly linked to an increased likelihood post-TIPS HE among cirrhotic patients.

Graphical Abstract

Available only for authorised users

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310-35. https://doi.org/10.1002/hep.28906. CrossRefPubMed

de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-52. https://doi.org/10.1016/j.jhep.2015.05.022. CrossRefPubMed

Perarnau JM, Le Gouge A, Nicolas C, d'Alteroche L, Borentain P, Saliba F, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol. 2014;60(5):962-8. https://doi.org/10.1016/j.jhep.2014.01.015.

Boyer TD, Haskal ZJ, American Association for the Study of Liver D. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology. 2010;51(1):306. https://doi.org/10.1002/hep.23383.

Yang Y, Fu S, Cao B, Hao K, Li Y, Huang J, et al. Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study. Hepatol Int. 2021. https://doi.org/10.1007/s12072-021-10188-5. CrossRefPubMed

Bhanji RA, Montano-Loza AJ, Watt KD. Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease. Hepatology. 2019;70(6):2193-203. https://doi.org/10.1002/hep.30686. CrossRefPubMed

Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611-44. https://doi.org/10.1002/hep.32049. CrossRefPubMed

Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75 Suppl 1(Suppl 1):S147-s62. https://doi.org/10.1016/j.jhep.2021.01.025.

Qiu J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan ML, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci U S A. 2013;110(45):18162-7. https://doi.org/10.1073/pnas.1317049110. CrossRefPubMedPubMedCentral

10.

Nardelli S, Lattanzi B, Merli M, Farcomeni A, Gioia S, Ridola L, et al. Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatology. 2019;70(5):1704-13. https://doi.org/10.1002/hep.30692. CrossRefPubMed

11.

Onuma T, Kamishima T, Shimamura T, Kawamura N, Yamashita K, Sutherland K, et al. Longitudinal CT study of sarcopenia due to hepatic failure after living donor liver transplantation. Quant Imaging Med Surg. 2018;8(1):25-31. https://doi.org/10.21037/qims.2018.01.07. CrossRefPubMedPubMedCentral

12.

Praktiknjo M, Book M, Luetkens J, Pohlmann A, Meyer C, Thomas D, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology. 2018;67(3):1014-26. https://doi.org/10.1002/hep.29602. CrossRefPubMed

13.

Chang KV, Chen JD, Wu WT, Huang KC, Lin HY, Han DS. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis. J Formos Med Assoc. 2019;118(4):833-42. https://doi.org/10.1016/j.jfma.2018.09.011. CrossRefPubMed

14.

Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner P, Cheungpasitporn W, Lukens F, et al. Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol. 2020;19(3):245-50. https://doi.org/10.1016/j.aohep.2019.06.007. CrossRefPubMed

15.

Pereira K, Carrion AF, Martin P, Vaheesan K, Salsamendi J, Doshi M, et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int. 2015;35(12):2487-94. https://doi.org/10.1111/liv.12956. CrossRefPubMed

16.

Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012;16(1):133-46. https://doi.org/10.1016/j.cld.2011.12.008. CrossRefPubMed

17.

Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013;25(1):85-93. https://doi.org/10.1097/MEG.0b013e328359a759. CrossRefPubMed

18.

Liu J, Ma J, Yang C, Chen M, Shi Q, Zhou C, et al. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement. Radiology. 2022:211172. https://doi.org/10.1148/radiol.211172.

19.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71. CrossRefPubMedPubMedCentral

20.

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160. CrossRefPubMedPubMedCentral

21.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5. https://doi.org/10.1007/s10654-010-9491-z. CrossRefPubMed

22.

Benmassaoud A, Roccarina D, Arico F, Leandro G, Yu B, Cheng F, et al. Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. Am J Gastroenterol. 2020;115(11):1911-4. https://doi.org/10.14309/ajg.0000000000000959. CrossRefPubMed

23.

Bhatia Kapoor P, Benjamin J, Tripathi H, Patidar Y, Maiwall R, Kumar G, et al. Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: Sarcopenia Adds Insult to Injury. Turk J Gastroenterol. 2023;34(4):406-12. https://doi.org/10.5152/tjg.2023.21964. CrossRefPubMedPubMedCentral

24.

Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, et al. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2017;15(6):934-6. https://doi.org/10.1016/j.cgh.2016.10.028. CrossRefPubMed

25.

Ronald J, Bozdogan E, Zaki IH, Kappus MR, Choi SS, Martin JG, et al. Relative Sarcopenia With Excess Adiposity Predicts Survival After Transjugular Intrahepatic Portosystemic Shunt Creation. AJR Am J Roentgenol. 2020;214(1):200-5. https://doi.org/10.2214/ajr.19.21655. CrossRefPubMed

26.

Xiong B, Yang C, Zhou C, Wu X, Huang S. TIPS placement as the first-line therapy to prevent variceal rebleeding in patients with cirrhosis and sarcopenia. Eur J Radiol. 2023;158:110630. https://doi.org/10.1016/j.ejrad.2022.110630. CrossRefPubMed

27.

Yang C, Zhu X, Liu J, Shi Q, Du H, Chen Y, et al. Development and Validation of Prognostic Models to Estimate the Risk of Overt Hepatic Encephalopathy After TIPS Creation: A Multicenter Study. Clin Transl Gastroenterol. 2022;13(3):e00461. https://doi.org/10.14309/ctg.0000000000000461. CrossRefPubMedPubMedCentral

28.

Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;65(6):1232-44. https://doi.org/10.1016/j.jhep.2016.07.040. CrossRefPubMedPubMedCentral

29.

Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther. 2020;51(1):64-77. https://doi.org/10.1111/apt.15571. CrossRefPubMed

30.

Kumar R, Prakash SS, Priyadarshi RN, Anand U. Sarcopenia in Chronic Liver Disease: A Metabolic Perspective. J Clin Transl Hepatol. 2022;10(6):1213-22. https://doi.org/10.14218/jcth.2022.00239. CrossRefPubMedPubMedCentral

31.

Shibamoto A, Namisaki T, Suzuki J, Kubo T, Iwai S, Tomooka F, et al. Hemoglobin and Endotoxin Levels Predict Sarcopenia Occurrence in Patients with Alcoholic Cirrhosis. Diagnostics (Basel). 2023;13(13). https://doi.org/10.3390/diagnostics13132218.

32.

Dasarathy J, McCullough AJ, Dasarathy S. Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances. Alcohol Clin Exp Res. 2017;41(8):1419-31. https://doi.org/10.1111/acer.13425. CrossRefPubMedPubMedCentral

33.

Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022;76(3):588-99. https://doi.org/10.1016/j.jhep.2021.11.006. CrossRefPubMed

34.

Patel RK, Chandel K, Tripathy TP, Mukund A. Complications of transjugular intrahepatic portosystemic shunt (TIPS) in the era of the stent graft - What the interventionists need to know? Eur J Radiol. 2021;144:109986. https://doi.org/10.1016/j.ejrad.2021.109986. CrossRefPubMed

35.

Jindal A, Jagdish RK. Sarcopenia: Ammonia metabolism and hepatic encephalopathy. Clin Mol Hepatol. 2019;25(3):270-9. https://doi.org/10.3350/cmh.2019.0015. CrossRefPubMedPubMedCentral

36.

Deutsch-Link S, Moon AM, Jiang Y, Barritt ASt, Tapper EB. Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends. Clin Ther. 2022;44(3):e45-e57. https://doi.org/10.1016/j.clinthera.2022.01.008.

37.

Qiu J, Tsien C, Thapalaya S, Narayanan A, Weihl CC, Ching JK, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303(8):E983-93. https://doi.org/10.1152/ajpendo.00183.2012. CrossRefPubMedPubMedCentral

38.

Kumar A, Davuluri G, Silva RNE, Engelen M, Ten Have GAM, Prayson R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology. 2017;65(6):2045-58. https://doi.org/10.1002/hep.29107. CrossRefPubMed

39.

Davuluri G, Krokowski D, Guan BJ, Kumar A, Thapaliya S, Singh D, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol. 2016;65(5):929-37. https://doi.org/10.1016/j.jhep.2016.06.004. CrossRefPubMedPubMedCentral

40.

Rombouts K, Bémeur C, Rose CF. Targeting the muscle for the treatment and prevention of hepatic encephalopathy. J Hepatol. 2016;65(5):876-8. https://doi.org/10.1016/j.jhep.2016.08.014. CrossRefPubMed

41.

42. Gioia S, Merli M, Nardelli S, Lattanzi B, Pitocchi F, Ridola L, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int. 2019;39(5):871-7. https://doi.org/10.1111/liv.14050. CrossRefPubMed

42.

Jahangiri Y, Pathak P, Tomozawa Y, Li L, Schlansky BL, Farsad K. Muscle Gain after Transjugular Intrahepatic Portosystemic Shunt Creation: Time Course and Prognostic Implications for Survival in Cirrhosis. J Vasc Interv Radiol. 2019;30(6):866-72 e4. https://doi.org/10.1016/j.jvir.2019.01.005.

43.

Johnston HE, Takefala TG, Kelly JT, Keating SE, Coombes JS, Macdonald GA, et al. The Effect of Diet and Exercise Interventions on Body Composition in Liver Cirrhosis: A Systematic Review. Nutrients. 2022;14(16). https://doi.org/10.3390/nu14163365.

44.

45. Lu Y, Niti M, Yap KB, Tan CTY, Zin Nyunt MS, Feng L, et al. Assessment of Sarcopenia Among Community-Dwelling At-Risk Frail Adults Aged 65 Years and Older Who Received Multidomain Lifestyle Interventions: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2019;2(10):e1913346. https://doi.org/10.1001/jamanetworkopen.2019.13346. CrossRefPubMedPubMedCentral

45.

Liao CD, Liao YH, Liou TH, Hsieh CY, Kuo YC, Chen HC. Effects of Protein-Rich Nutritional Composition Supplementation on Sarcopenia Indices and Physical Activity during Resistance Exercise Training in Older Women with Knee Osteoarthritis. Nutrients. 2021;13(8). https://doi.org/10.3390/nu13082487.

Title: Association between sarcopenia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review and meta-analysis
Authors: Yuanyuan Li
Yuxin Guo
Xiaoze Wang
Langli Gao
Publication date: 19-11-2023
Publisher: Springer US
Keywords: Hepatic Encephalopathy
Hepatic Encephalopathy
Sarcopenia
Liver Cirrhosis
Published in: Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-023-04095-6

Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

Prof. Mike Lean

Prof. Falko Sniehotta

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Graphical Abstract

Please log in to get access to this content

Keynote Webinar | Spotlight on Diet and Diabetes